Lupin gets USFDA nod to market colonoscopy drug

Priya sundarajan Updated - January 13, 2018 at 01:29 AM.

BL30LUPIN1

Pharma major Lupin Ltd has received final approval from the USFDA to market sodium sulfate, potassium sulfate, magnesium sulfate oral solution used in colonoscopy.

In a BSE filing, Lupin said “it has received final approval for its sodium sulfate, potassium sulfate, magnesium sulfate oral solution, 17.5 g/3.13 g/ 1.6 g per ounces from the United States Food and Drug Administration (FDA) to market a generic version of Braintree Laboratories’ Suprep Bowel Prep Kit.”

Lupin said it will commence promoting the product shortly.

The approved product is indicated for cleansing of the colon in preparation of colonoscopy in adults. Suprep Bowel Prep Kit had US sales of USD 207.2 million.

Shares of Lupin were trading 0.44 per cent higher at Rs 1,470.25 on the BSE.

Published on February 28, 2017 06:22